title: Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
abstract: Isolated 20q deletion is common in MDS and considered of good prognosis, but no large series have been reported. We compared characteristics of 62 MDS patients with isolated del 20q, 36 patients with del 20q and other cytogenetic abnormalities, and 1335 MDS patients without del20q. Significant differences between MDS with isolated del 20q and patients without del 20q were lower platelet count (mean 144 vs. 196 G/l, p=0.005), lower marrow blast count (mean 3.9% vs. 5.6%, p=0.0008), and higher reticulocyte count (mean 72.5 vs. 51.7 G/l, p=0.04). Ten (16%) patients with isolated del 20q had Hb>12 g/dl and platelets <100 G/l, compared to 7.3% of patients without del 20q (p=0.025). Review of marrow slides of those 10 patients showed that could be readily identified as MDS prior to cytogenetics. Fourteen percent of patients with isolated del 20q progressed to AML compared to 11% with one and 24% with several additional abnormalities. Median survival was 54 months in patients with isolated del 20q, not reached and 12 months for del 20q with one and several additional abnormalities, respectively (p=0.035) confirming the favorable prognosis of del 20q without complex abnormalities.
authors.affiliation: Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Service d'Hématologie Clinique, University Paris XIII, Bobigny, France.
authors.forename: Thorsten
authors.initials: T
authors.lastname: Braun
authors.forename: Stéphane
authors.initials: S
authors.lastname: de Botton
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Taksin
authors.forename: Sophie
authors.initials: S
authors.lastname: Park
authors.forename: Odile
authors.initials: O
authors.lastname: Beyne-Rauzy
authors.forename: Valérie
authors.initials: V
authors.lastname: Coiteux
authors.forename: Rosa
authors.initials: R
authors.lastname: Sapena
authors.forename: Anne
authors.initials: A
authors.lastname: Lazareth
authors.forename: Geneviève
authors.initials: G
authors.lastname: Leroux
authors.forename: Khaled
authors.initials: K
authors.lastname: Guenda
authors.forename: Bruno
authors.initials: B
authors.lastname: Cassinat
authors.forename: Michaela
authors.initials: M
authors.lastname: Fontenay
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
authors.forename: Agnès
authors.initials: A
authors.lastname: Guerci
authors.forename: François
authors.initials: F
authors.lastname: Dreyfus
authors.forename: Dominique
authors.initials: D
authors.lastname: Bordessoule
authors.forename: Aspasia
authors.initials: A
authors.lastname: Stamatoullas
authors.forename: Sylvie
authors.initials: S
authors.lastname: Castaigne
authors.forename: Christine
authors.initials: C
authors.lastname: Terré
authors.forename: Virginie
authors.initials: V
authors.lastname: Eclache
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.forename: Lionel
authors.initials: L
authors.lastname: Adès
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D002890:Chromosomes, Human, Pair 20 / Q000235:genetics*; D005260:Female; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D015996:Survival Rate